A large number of G4 ligands like porphyrin derivatives, acridine derivatives, pyridine derivatives, and natural alkaloids have been tailored to act as anticancer therapeutics by stabilizing G-quadruplexes and have been summarized elegantly by Teng et al. For instance, the potential G4 ligands reported for c-myc includes TMPy4, BRACO-19, and pyridostatin, which suppresses the growth and proliferation of breast cancer cells, retinoblastoma cells, and melanoma cells (Mikami-Terao et al., 2009; Rapozzi et al., 2014; Asamitsu et al., 2019; Konieczna et al., 2019). Here, MYC is linked to retinoblastoma.